COMPOSITION:

Each LuciLenva capsule contains: 12.25mg Lenvatinib mesylate equivalent to Lenvatinib.………10mg

INDICATION:  

LuciLenva is a kinase inhibitor that is indicated:

1. For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).

2. In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC).

3. For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).  

DOSAGE AND USE:

1. DTC: The recommended dosage is 24 mg orally once daily.  

2. RCC: The recommended dosage is 18 mg orally with everolimus 5 mg orally once daily.  

3. HCC: The recommended dosage is based on actual body weight:

· 12 mg orally once daily for patients greater than or equal to 60 kg

· 8 mg orally once daily for patients less than 60 kg.  

Capsules should be swallowed whole & not chewed or crushed.  

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciLenva during Pregnancy and Lactation.